Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $16,508.91 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 627 shares of Stoke Therapeutics stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $26.33, for a total value of $16,508.91. Following the sale, the general counsel directly owned 20,598 shares of the company’s stock, valued at $542,345.34. This trade represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, August 18th, Jonathan Allan sold 2,861 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total value of $91,637.83.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $25.62 on Monday. Stoke Therapeutics, Inc. has a fifty-two week low of $20.32 and a fifty-two week high of $40.22. The firm has a market capitalization of $1.65 billion, a PE ratio of -7.67 and a beta of 1.26. The stock’s 50-day simple moving average is $29.91 and its 200-day simple moving average is $31.15.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The business had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. On average, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in STOK. Tidal Investments LLC increased its position in Stoke Therapeutics by 16.1% in the 2nd quarter. Tidal Investments LLC now owns 9,917 shares of the company’s stock valued at $324,000 after acquiring an additional 1,377 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Stoke Therapeutics in the 2nd quarter valued at approximately $959,000. Corient Private Wealth LP acquired a new position in shares of Stoke Therapeutics in the second quarter valued at approximately $1,009,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $443,000. Finally, Seven Fleet Capital Management LP acquired a new stake in shares of Stoke Therapeutics during the second quarter worth $255,000.

Analyst Ratings Changes

STOK has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a research report on Friday, August 21st. They issued an “overweight” rating and a $40.00 target price on the stock. Canaccord Genuity Group reduced their price target on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Guggenheim restated a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Wedbush boosted their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company’s approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes.

Stoke’s lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene.